US Imposes 100% Pharma Tariff: India's Generics Exempt for Now

US Announces Steep Tariffs on Patented Drugs

The United States government has announced a significant trade measure, imposing a 100% tariff on all imported patented pharmaceutical products. Citing national security and supply chain vulnerabilities identified in a Section 232 investigation, the move is designed to encourage drug manufacturers to shift production to American soil and reduce reliance on foreign suppliers. The tariffs are scheduled for a phased implementation beginning in July and September 2026. While the policy targets key drug-producing nations like Ireland, Switzerland, and Germany, its implications for India, a major global pharmaceutical supplier, are complex and multifaceted.

Generics Exemption Provides Immediate Relief for India

For India's pharmaceutical sector, the most critical detail in the announcement is the explicit exemption of generic drugs. A White House official clarified that generics, which form the backbone of India's pharma exports, "shall not be subject to Section 232 tariffs" at this time. This exclusion provides a significant buffer for Indian drugmakers, as approximately 88-90% of the country's pharmaceutical exports to the US consist of generic formulations. In the fiscal year 2025, India's pharma exports to the US were valued at over $10.5 billion, underscoring the importance of this exemption. The decision ensures that the bulk of India's pharmaceutical trade with the US can continue without immediate disruption, protecting a vital revenue stream for the industry.

Long-Term Uncertainty and Hidden Risks

Despite the short-term relief, the policy introduces a considerable degree of long-term uncertainty. Officials have stated that the exemption for generics is temporary and will be re-evaluated. The US Commerce Department is tasked with assessing the progress of reshoring generic drug manufacturing and may recommend extending tariffs if domestic production does not increase sufficiently. This review, expected to conclude in early 2026, creates a policy overhang that could influence future investment and strategic planning for Indian firms. The risk that the tariff scope could be expanded to include generics remains a primary concern for the industry.

Impact on Patented Drugs and Supply Chains

While the majority of Indian exports are safe, companies involved in the manufacturing of patented drugs, specialty medicines, and active pharmaceutical ingredients (APIs) face direct challenges. These firms, which often operate as contract manufacturers for multinational corporations, will be subject to the 100% tariff unless they have or establish manufacturing facilities in the US. This could compress profit margins, disrupt global supply chains, and force companies to either absorb the steep costs or pass them on to consumers. The policy incentivizes a shift in production, potentially redirecting future capital investment away from India and toward the US.

Indian Stock Market Reacts to Policy News

The announcement sent ripples through the Indian stock market, triggering sharp intraday swings and a sell-off in pharmaceutical stocks. The Nifty Pharma index experienced a sudden dip as investors reacted to the news and the associated uncertainty. The volatility highlights the sector's sensitivity to US trade policy changes.

Industry Leaders Urge Caution

Industry experts and association leaders have acknowledged the temporary relief provided by the generics exemption but have also urged caution. Siddharth Mittal, CEO and Managing Director of Biocon Limited, stated that while the exclusion prevents immediate disruption, the move introduces "a layer of policy uncertainty." Similarly, representatives from the Indian Drug Manufacturers’ Association (IDMA) and the Pharmaceuticals Export Promotion Council of India (Pharmexcil) noted that while the immediate impact is limited, it is prudent for companies to prepare for future policy shifts and build risk-mitigation strategies.

Strategic Imperatives for the Future

The US tariff policy serves as a clear signal of increasing protectionism. For India's pharmaceutical industry, this necessitates a strategic re-evaluation. Key imperatives include diversifying export markets to reduce over-reliance on the US, strengthening domestic demand, and accelerating investment in research and development. Focusing on higher-value segments like complex generics, biosimilars, and biologics will be crucial for maintaining a competitive edge. Some companies may also accelerate plans to establish or expand manufacturing operations within the US to bypass tariff barriers and secure their market position.

Conclusion: Insulated but Not Immune

In summary, India's pharmaceutical sector has been largely insulated from the immediate impact of the 100% US tariff on patented drugs due to the crucial exemption for generics. However, this should not be mistaken for complete immunity. The temporary nature of the exemption and the clear US policy goal of onshoring production create significant long-term risks. The industry must navigate this new landscape by enhancing its capabilities, diversifying its markets, and preparing for potential policy shifts that could emerge following the 2026 review.